BHST - BioHarvest Sciences Forward P/S Multiple
Biosynthesis scaling risks and EU regulatory barriers are exerting moderate pressure on BioHarvest Sciences (BHST). On GURU.Markets, the forward price-to-sales valuation chart demonstrates a price vector where the value has stabilized at 1.00. The business fundamentals rely on the purity of soil-free cell cultivation, while stable demand for nutraceuticals minimizes the stock's dependence on macroeconomic cycles.
Metric breakdowns and analytics for BioHarvest Sciences Inc (BHST)
- current price and projected stock value:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital BioHarvest Sciences|BHST - Long-Term Debt to Capital|Short-Term Debt to Equity BioHarvest Sciences|BHST - Aggregate Debt Obligations|Debt to Book Value BioHarvest Sciences Inc|BHST - Company Long-Term Debt|Company Short-Term Debts BioHarvest Sciences|Quick Liquidity bioharvest.com
- business earnings and investment ratios data:
BHST - Net Financial Result|Future Profit BioHarvest Sciences|BHST - Market Price to Net Income Ratio|Projected Price to Earnings BioHarvest|BHST - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioHarvest Sciences Inc|BHST - Operating income before deduction of amortization|Net earnings per share (EPS TTM) BioHarvest Sciences|BHST - Net earnings per share for the last 12 months|Quarterly EPS earnings growth bioharvest.com|BHST - Expected net earnings per share growth this year|Earnings growth forecast for next year BioHarvest Sciences
- revenue and sales details:
Summary company analysis:BioHarvest Sciences Inc. (BHST)
BioHarvest Sciences (BHST) is transforming the agricultural sector through cellular bio-growth, making the expected revenue multiple a key indicator of the efficiency of scaling bioreactor capacities. This metric correlates current market value with projected revenue, allowing for an assessment of the risk of asset overvaluation should there be a deviation from resource optimization plans and sales expansion rates.
Who BioHarvest Sciences competes with
Forward P/S Multiple HLN (Haleon)|Kenvue Inc - Price-to-Projected Revenue Ratio|Verona Pharma Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Jyong Bio MENS|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio amneal.com (AMRX)|PRGO (Perrigo) - Forward P/S Multiple|ALVO: Forward Price to Sales|Forward P/S Multiple LQDA|Forward P/S Multiple Galapagos Corp (GLPG)|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|Forward Price to Sales MNKD|AMPH: Forward Price-to-Revenue Multiple|PCRX: Price-to-Projected Revenue Ratio|SPRY: Forward P/S Multiple|Market Cap to Future Revenue Ratio Theravance Corp (TBPH)|Price-to-Projected Revenue Ratio Aquestive Therapeutics|scPharma (SCPH) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|Price to Expected Revenue Ratio TNXP|China SXT Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales EPRX|EXOZ - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Oramed Pharmaceuticals ORMP|ENTX: Forward P/S Multiple|Forward Price-to-Revenue Multiple MindWalk Holdings, Inc.|ABVC (ABVC BioPharma Inc) - Forward P/S Multiple|Cumberland Corp (CPIX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple QNTM|FGEN - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|RANI: Market Cap to Projected Revenue|Synergy CHC Corporation - Forward P/S Multiple|Rallybio Corporation (RLYB) - Forward Price-to-Revenue Multiple|LEXX: Forward P/S Multiple|Market Cap to Future Revenue Ratio pulmatrix.com (PULM)|Price-to-Projected Revenue Ratio Pheton Holdings Limited|Aptorum (APM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple LYRA|Price-to-Projected Revenue Ratio IBO (Impact BioMedical, Inc.)|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward Price to Sales YCBD|PRFX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Altamira Therapeutics CYTO|LIPO (Lipella) - Forward Price-to-Revenue Multiple|OPTN: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP
